EBMT 2022 | Management of newly diagnosed patients with multiple myeloma not eligible for transplantation
Maximilian Merz, MD, Leipzig University, Leipzig, Germany, Roswell Park Comprehensive Center Institute, Buffalo, NY, comments on the management of patients with multiple myeloma not eligible for transplant, where a paradigm shift has been observed after the introduction of CD38 antibodies to upfront therapy, with higher rates of progression-free survival (PFS) and overall survival (OS) and long-lasting remissions. Data from the ALCYONE (NCT02195479) and MAIA (NCT02252172) trials led to the approval of several combinations of daratumumab, with a notable outcome improvement in elderly and frail patients. Dr Merz considers that the standard of care should point to antibody plus lenalidomide-dexamethasone (Rd) or bortezomib-melphalan-prednisone (VMP), but more data on quadruplet therapy for ineligible patients is needed. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Advisory board: Janssen, BMS/Celgene, Amgen, GSK, Sanofi
Consultancy: onkowissen.de, Hexal, oncologyinformationservice
Travel support: Amgen, BMS/Celgene, Janssen, Abbvie, Takeda
Research support: Takeda, BMS/Celgene
